Authors
Latest:
Lutz Frolich, MD, PhD: Learning from Negative TrialsLutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.
Latest:
Justifying Use of CGRP mAbs in Pediatric Patients With MigraineWhat happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?
Latest:
Jacqueline French, MD: Barriers to Identifying Nonmotor SeizuresThe director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.
Latest:
Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare ConditionsThe chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.
Latest:
Andre Machado, MD, PhD: Multidisciplinary Treatment in Movement DisordersThe Chairman of the Neurological Institute at Cleveland Clinic provided insight into the multidisciplinary decision-making process for patients with movement disorders at the center.
Latest:
Therapies for Children and Adults with Dravet SyndromeThe panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.
Latest:
Highlighting Genetic Discoveries and Therapeutic Developments in ALS: Matthew B. Harms, MDThe associate professor of neurology at Columbia University talked about a track session that he will be chairing at the upcoming MDA conference on amyotrophic lateral sclerosis genetic research. [WATCH TIME: 5 minutes]
Latest:
Future Treatment of hATTR AmyloidosisAnalysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
Latest:
2020 Epilepsy Review: Much to Be Excited AboutDespite 2020 being a challenging year for those in medicine, the epilepsy therapeutic space featured a number of key steps forward.
Latest:
Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight OpenThe smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.
Latest:
Robert Califf, MD, Nominated by Biden Administration as Next FDA CommissionerHaving previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.
Latest:
Davangere Devanand, MBBS, MD: Challenges in Symptom Management in Alzheimer DiseaseDavangere P. Devanand, MBBS, MD, discussed the possibility of neurologists prescribing low-dose lithium for patients with Alzheimer and symptoms of agitation.
Latest:
Aducanumab Reinvigorates the Fight Against Alzheimer DiseaseThe chief medical officer of ProMIS Neurosciences comments on how aducanumab will help propel innovation needed to drive the next generation of therapies for Alzheimer disease.
Latest:
Anli Liu, MD: Responsive Neurostimulation System for Cognition in EpilepsyLiu discussed this work and the findings of this proof-of-principle trial in memory in epilepsy.
Latest:
Novel and Emerging Targets in Multiple SclerosisExperts in neurology share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.
Latest:
Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSAThe medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.
Latest:
Zhibin Chen, PhD: Treatment Gap in Patients with Newly Diagnosed EpilepsyDespite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.
Latest:
Shimrit Uliel-Sibony, MD: Can Patients Develop a CBD Tolerance?Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.
Latest:
Trevor Resnick, MD: Treating Epilepsy By Blending Technology, Genetics, and PharmacologicsThe pediatric epileptologist at Nicklaus Children’s Hospital spoke about the future of epilepsy and shared which studies of the condition that he’s been keeping an eye on.
Latest:
Asher J. Albertson, MD, PhD: Getting Interventions to Stroke PatientsAlbertson discussed this facet of stroke care, and all the things being done outside just the clinic to help improve outcomes.
Latest:
Shift in Treatment Paradigm for Dravet Syndrome: Joseph Sullivan, MDThe director of the Pediatric Epilepsy Center at UCSF provided perspective on the advances in the treatment of Dravet syndrome, emerging research concepts in the field, and the influence of genetic testing. [WATCH TIME: 5 minutes]
Latest:
Spinal Muscular Atrophy and COVID-19: Guidance and Resources for ProvidersAdvocacy organization Cure SMA provides guidance for health care providers caring for patients with SMA during the ongoing COVID-19 pandemic.
Latest:
Optical Coherence Tomography Angiography Helps Differentiate MS and NMOSDAlthough existing research has shown structural differences between multiple sclerosis and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.
Latest:
Jeffery Vance, MD, PhD: Role of Genetics in Distinguishing Alzheimer RiskThe professor of neurology and founding chair of the John T. Macdonald Foundation Department of Human Genetics at the University of Miami spoke about how the risk of Alzheimer disease differs between ethnic groups, despite being associated with the same genetic marker.
Latest:
Results from the Subgroup Analysis of BECOME Caregiver Survey: Robert Iannone, MD, MSCEThe executive vice president of Global Head of Research and Development at Jazz Pharmaceuticals, spoke on the results from the BECOME study presented at the 2022 AES Conference. [WATCH TIME: 6 minutes]
Latest:
Advice for Physicians and the Multiple Sclerosis CommunityThe panel shares final advice for the multiple sclerosis community.
